SNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sanofi SA (SNY) is not a strong buy for a beginner, long-term investor at this moment. While there are some positive developments, such as Dupixent's FDA approval, the overall sentiment from analysts, lack of strong technical signals, and uncertainty surrounding leadership changes and pipeline challenges suggest a cautious approach. Holding the stock or waiting for more clarity on its growth trajectory would be prudent.
The MACD is positive and expanding, indicating a bullish trend. The RSI is neutral at 66.151, and moving averages are converging, showing no clear directional momentum. The stock is trading near resistance levels (R1: 48.037, R2: 48.631), suggesting limited immediate upside.
Dupixent's FDA approval for multiple indications, including allergic fungal rhinosinusitis, is a positive development that could support revenue growth in the near term. Hedge funds are significantly increasing their positions in Sanofi, which indicates institutional confidence.
Analyst downgrades and reduced price targets highlight concerns about Sanofi's pipeline and strategic direction. The departure of CEO Paul Hudson and the transition to new leadership under Belen Garijo adds uncertainty. Limited pipeline catalysts and strategic risks are also noted by analysts.
No financial data is available for the latest quarter, making it difficult to assess recent growth trends.
The majority of analysts have downgraded Sanofi to Neutral from Buy, citing pipeline challenges, strategic risks, and leadership uncertainty. Price targets have been reduced across the board, reflecting cautious sentiment.
